Format

Send to

Choose Destination
Infect Disord Drug Targets. 2018;18(1):15-22. doi: 10.2174/1871526517666170505122800.

HAART in HIV/AIDS Treatments: Future Trends.

Author information

1
School of Life Sciences, Shanghai University, Shanghai 200444, China.
2
College of Science, Shanghai University, Shanghai 200444, China.
3
GITAM University, Viskhapatnam, AP, India.
4
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Abstract

AIDS (acquired immune deficient syndrome) is a deadly human viral infectious disease caused by HIV (human immune-deficient virus) infection. Almost every AIDS patient losses his/her life before mid 1990s. AIDS was once the 1st disease killer in US (1993). After one decade hard work, antiviral drug cocktails-high active anti-retroviral therapy (HAART) have been invented for almost all HIV infection treatments. Due to the invention of HAART, 80-90% HIV/AIDS patients still effectively response to HAART for deadly AIDS episode controls and life saving. Yet, this type of HIV therapeutics is incurable. HIV/AIDS patients need to take HAART medications regularly and even life-long. To counteract this therapeutic drawback, more revolutionary efforts (different angles of therapeutic modes/attempts) are urgently needed. In this article, the major progresses and drawbacks of HIV/AIDS chemotherapy (HAART) to HIV/AIDS patients have been discussed. Future trends (updating pathogenesis study, next generations of drug developments, new drug target discovery, different scientific disciplinary and so on) are highlighted.

KEYWORDS:

HAART; HIV cure; HIV latency; HIV reservoirs; antiviral therapy; biotherapy; drug delivery system; integrase inhibitors; medicinal chemistry; pharmacogenomics

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center